P. Sran

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

T. Waldmann, R. Nussenblatt, C. Goldman, 1999, Proceedings of the National Academy of Sciences of the United States of America.

A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin.

R. Nussenblatt, S. Whitcup, D. Herman, 1993, American journal of ophthalmology.

High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.

T. Waldmann, R. Nussenblatt, S. Yeh, 2008, Journal of autoimmunity.

Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease.

S. Gangaputra, R. Nussenblatt, S. Yeh, 2011, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

T. Waldmann, Darby J. S. Thompson, S. Srivastava, 2003, Journal of autoimmunity.

Association of thyroid disease with retinitis pigmentosa and gyrate atrophy.

M. Kaiser-Kupfer, S. Whitcup, M. Podgor, 1996, American journal of ophthalmology.

The relocation syndrome in mentally retarded individuals.

P. Sran, W. E. Cchran, G. A. Varano, 1977, Mental retardation.